Current Report Filing (8-k)
December 06 2022 - 04:25PM
Edgar (US Regulatory)
0000704562 false 0000704562 2022-12-06
2022-12-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC
20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 6, 2022
AVID BIOSERVICES, INC.
(Exact name of registrant as specified in its charter)
Delaware |
001-32839 |
95-3698422 |
(State
of other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
14191 Myford Road,
Tustin,
California
92780
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code:
(714)
508-6100
__________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425). |
|
☐ |
Soliciting material pursuant to Rule 14A-12 under the Exchange
Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class |
Trading Symbol |
Name of each exchange on which registered |
Common Stock, $0.001 par value per share |
CDMO |
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of
1933(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
☐ Emerging growth company
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
ITEM 2.02 |
RESULTS OF
OPERATIONS AND FINANCIAL CONDITION |
On December 6, 2022, Avid Bioservices, Inc. (the “Company”) issued
a press release to report the Company’s financial results for the
second quarter ended October 31, 2022. A copy of the press release
is attached to this Current Report on Form 8-K as Exhibit 99.1. No
additional information is included in this Current Report on Form
8-K.
The information included in this Current Report on Form 8-K,
including the exhibit hereto, shall not be deemed “filed” for
purposes of, nor shall it be deemed incorporated by reference in,
any filing under the Securities Act of 1933 or the Securities
Exchange Act of 1934, except as expressly set forth by specific
reference in such a filing.
ITEM 7.01 |
REGULATION FD DISCLOSURE |
On December 6, 2022, at 4:30 p.m. EST/1:30 p.m. PST, the Company
will host a conference call to discuss its second quarter ended
October 31, 2022 financial results. The webcast of the conference
call will be archived on the Company’s website for approximately 30
days.
ITEM 9.01 |
FINANCIAL STATEMENTS
AND EXHIBITS |
(d) Exhibits. The following material is filed as an exhibit to this
Current Report on Form 8-K:
Exhibit
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
AVID
BIOSERVICES, INC. |
|
|
|
|
|
|
|
|
|
Date: December 6, 2022 |
By: |
/s/ Daniel R. Hart |
|
|
|
Daniel R.
Hart |
|
|
|
Chief Financial
Officer |
|
EXHIBIT INDEX
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to May 2023
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From May 2022 to May 2023